Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $7 | $21 |
| - Cash | $5 | $3 | $4 | $7 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | -$2 | $0 | $4 | $15 |
| Revenue | $14 | $13 | $13 | $13 |
| % Growth | 12.2% | -4% | 5.1% | – |
| Gross Profit | $5 | $5 | $4 | $4 |
| % Margin | 38.2% | 37.3% | 33.7% | 31.6% |
| EBITDA | -$4 | -$5 | -$4 | -$6 |
| % Margin | -25% | -35.5% | -33.5% | -45.1% |
| Net Income | -$3 | -$5 | -$5 | -$5 |
| % Margin | -24.2% | -38% | -38.8% | -40.3% |
| EPS Diluted | -2.79 | -5.32 | -15.18 | -19.17 |
| % Growth | 47.6% | 65% | 20.8% | – |
| Operating Cash Flow | -$0 | -$2 | -$6 | -$4 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$2 | -$6 | -$4 |